Malignant Pleural Mesothelioma market projecting a CAGR of 7.6% during the forecast period, 2020-2026

Published | March 2020

According to BlueWeave Consulting, the global Malignant Pleural Mesothelioma market anticipated to grow by Significant CAGR of 7.6% during the forecast period 2020-2026.The global market for malignant pleural mesothelioma is expected to receive a favorable boost from increased healthcare expenditure in many parts of the world, combined with the availability of better treatment prognosis for malignant pleural mesothelioma.

Malignant pleural mesothelioma is a rare and aggressive cancer that develops in a thin tissue layer called pleura around the lungs. Microscopic inhalation of asbestos fibers causes malignant pleural mesothelioma. According to the NIH, once the individual inhales asbestos particles, the human body fails to remove is about 20 per million inhabitants, and it is -globally. Overall, there's also increased acceptance of combination therapies on the global malignant pleural mesothelioma sector. Several organizations support the combined use of chemotherapy and immune-oncology treatments in treating malignant pleural mesothelioma. The rate of diagnosis of malignant pleural mesothelioma is poor because of the late appearance of the symptoms. Malignant pleural mesothelioma prognosis, therefore, gets bleak and makes it difficult to treat cancer effectively.

Rising exposure to asbestos is the key factor for market growth

Asbestos-exposed individuals are at increased risk of developing malignant pleural mesothelioma. Within contaminated areas, as opposed to non-polluted areas, the risk of malignant pleural mesothelioma is increased by 2 to 10 fold. People who work in mines and are heavily exposed to asbestos are usually at a higher risk of developing malignant pleural mesothelioma. About 2-18 percent of miners and those working in plants containing asbestos are diagnosed with malignant pleural mesothelioma. People who are genuinely interested in the use of asbestos as one of the raw materials are not even spared. It is disturbing to note that people who live near these factories are put at risk of contracting the disease. However, people exposed to a high dose of radiation, zeolites (minerals chemically contaminated with asbestos), and those suffering from simian virus 40 are at risk of developing malignant pleural mesothelioma and contribute indirectly to the global market for malignant pleural mesothelioma with the significant growth rate.

Pemetrexed and cisplatin as the typical first-line treatment of malignant pleural mesothelioma booming the drug segment

Pemetrexed and cisplatin are the standard first-line treatment of pleural mesothelioma with malignancy. It is the most effective chemotherapy treatment. In a recent study to test cisplatin and Pemetrexed called Mesothelioma Avastin Cisplatin Pemetrexed Trial (MAPS), the addition of bevacizumab in patients with minimal side effects of malignant pleural mesothelioma showed significantly improved survival rates. Focus on getting approvals for effective combination therapy. It is believed that exposure to asbestos leads to malignant pleural mesothelioma, and despite the limitations on the global use of asbestos, mesothelioma cases are expected to decline in the forthcoming years.

Nonetheless, those findings are not confirmed by the number of malignant pleural mesothelioma cases. It was observed that there is a growing trend of cases of malignant mesothelioma in men. This specific aspect drives Pemetrexed revenue growth and the combination segment.

North America expected to witness significant growth in the market in the upcoming years

North America is the market leader in malignant pleural mesothelioma led by Europe due to higher incidence and prevalence rates, an increase in the geriatric population, and increased demand for advanced therapies. The Asia Pacific is an emerging market for malignant pleural mesothelioma due to healthcare infrastructure development, patient awareness, and increased government spending in the healthcare sector. Low patient awareness, lack of proper treatment, and high therapy costs are factors that narrow the demand for malignant pleural mesothelioma in Middle East & Africa.

Browse Detailed Table of Contents, “Malignant Pleural Mesothelioma Market Drug Class (Premetrexed and Combination, Cisplatin and Combination, Carboplatin and Combination, Gemcitabine and Combination, Vinorelbine and Combination and Other Combination), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Oncology Centers), By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Trend Analysis, Competitive Market Share & Forecast, 2016-26


Malignant Pleural Mesothelioma: Competitive Landscape

Malignant Pleural Mesothelioma market is fragmented owing to the presence of number of large-sized companies that hold the majority share of AstraZeneca Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Eli Lilly and Company, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan N.V., Fresenius Kabi AG, Sun Pharmaceuticals Industries Ltd, Corden Pharma International GmbH, Concordia International Corp and Other Prominent Players.